# A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

> **NCT06667544** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ranok Therapeutics (Hangzhou) Co., Ltd.** · enrollment: 152 (estimated)

## Conditions studied

- KRAS G12D Mutation

## Interventions

- **DRUG:** RNK08954-01

## Key facts

- **NCT ID:** NCT06667544
- **Lead sponsor:** Ranok Therapeutics (Hangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2026-12
- **Final completion:** 2027-07
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2025-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06667544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06667544, "A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06667544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*